Fujifilm Diosynth dumps another $454M into its supply chain, this time at a facility in the UK
Fujifilm Diosynth Biotechnologies is in the middle of a monumental point in the company’s 10-year history, and the CDMO is about to grow even more, as it sets out to be the “beating heart” of the UK’s North East Life Sciences ecosystem.
A site in Billingham, Teeside, UK will receive a $453.72 million investment package from the manufacturer to double the existing footprint and create the largest multi-modal biopharmaceutical manufacturing site in the UK, bringing another 350 jobs to the region by late 2023.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.